menu
    • menu
    [{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Everest Medicines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Termination","leadProduct":"mRNA-Based Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Providence Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Providence Therapeutics \/ Everest Medicines","highestDevelopmentStatusID":"4","companyTruncated":"Providence Therapeutics \/ Everest Medicines"},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"PTX-COVID-19-B","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Providence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Providence Therapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Providence Therapeutics \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PTX-COVID-19-B","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Providence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Providence Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Providence Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Everest Medicines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"PTX-COVID-19-B","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Providence Therapeutics","amount2":0.59999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.59999999999999998,"dosageForm":"Injection","sponsorNew":"Providence Therapeutics \/ Everest Medicines","highestDevelopmentStatusID":"8","companyTruncated":"Providence Therapeutics \/ Everest Medicines"},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PTX-COVID-19-B","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Providence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Providence Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Providence Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PTX-COVID-19-B","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Providence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Providence Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Providence Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"PTX-COVID-19-B","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Providence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Providence Therapeutics \/ Providence Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Providence Therapeutics \/ Providence Therapeutics"},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Next Generation Manufacturing Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"PTX-COVID-19-B","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Providence Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Providence Therapeutics \/ Next Generation Manufacturing Canada","highestDevelopmentStatusID":"8","companyTruncated":"Providence Therapeutics \/ Next Generation Manufacturing Canada"},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PTX-COVID-19-B","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Providence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Providence Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Providence Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Everest Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-Based Rabies Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Providence Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Providence Therapeutics \/ Everest Medicines","highestDevelopmentStatusID":"4","companyTruncated":"Providence Therapeutics \/ Everest Medicines"},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"PTX-COVID19-B","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Providence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Providence Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Providence Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"PTX-COVID19-B","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Providence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Providence Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Providence Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"University Health Network","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Providence Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Providence Therapeutics \/ University Health Network","highestDevelopmentStatusID":"2","companyTruncated":"Providence Therapeutics \/ University Health Network"}]

    Find Clinical Drug Pipeline Developments & Deals by Providence Therapeutics

    Menu

    Providence Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Providence Therapeutics

                            Canada arrow
                            Florida Innovation
                            Not Confirmed

                            Providence Therapeutics

                            Canada arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-Based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Everest Medicines

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Everest Medicines Announces Termination of Collaboration Agreements with Providence

                            Details : Through the termination, Everest will continue to develop its products utilizing the mRNA-based vaccine and will own full intellectual property rights and full global rights of those products.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            February 18, 2024

                            Lead Product(s) : mRNA-Based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Everest Medicines

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Providence Therapeutics

                            Canada arrow
                            Florida Innovation
                            Not Confirmed

                            Providence Therapeutics

                            Canada arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : University Health Network

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Providence Therapeutics Announces Partnership with University Health Network (UHN) for mRNA Therapeutic Discov...

                            Details : The collaboration will allow Providence and UHN to develop mRNA-based vaccines and therapeutics for those living with difficult to treat cancers and infectious diseases, using Providence’s proprietary mRNA platform technology.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 02, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : University Health Network

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Providence Therapeutics

                            Canada arrow
                            Florida Innovation
                            Not Confirmed

                            Providence Therapeutics

                            Canada arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-Based Rabies Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Everest Medicines

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Providence Therapeutics Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Conc...

                            Details : The candidate was developed in partnership with Everest Medicines utilizing Providence’s clinically validated mRNA technology platform. Providence’s candidate also induced a significantly higher degree of T-cell-mediated immune response than the comp...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            December 15, 2022

                            Lead Product(s) : mRNA-Based Rabies Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Everest Medicines

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Providence Therapeutics

                            Canada arrow
                            Florida Innovation
                            Not Confirmed

                            Providence Therapeutics

                            Canada arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PTX-COVID-19-B

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Providence Therapeutics Presents Phase 2 Data on its mRNA COVID-19 Vaccine Candidate PTX-COVID19-B at the 2022...

                            Details : PTX-COVID19-B is an mRNA vaccine candidate designed to generate potent neutralizing antibodies against the spike protein of SARS-CoV-2 and promote immunity to COVID-19.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            November 28, 2022

                            Lead Product(s) : PTX-COVID-19-B

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Providence Therapeutics

                            Canada arrow
                            Florida Innovation
                            Not Confirmed

                            Providence Therapeutics

                            Canada arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PTX-COVID-19-B

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Providence Announces Positive Top-Line Data from Phase 2 Primary Immunization Trial of its mRNA Vaccine Candid...

                            Details : PTX-COVID19-B is an mRNA vaccine candidate designed to generate potent neutralizing antibodies against the spike protein of SARS-CoV-2 and promote immunity to COVID-19.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            October 19, 2022

                            Lead Product(s) : PTX-COVID-19-B

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Providence Therapeutics

                            Canada arrow
                            Florida Innovation
                            Not Confirmed

                            Providence Therapeutics

                            Canada arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PTX-COVID19-B

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Stud...

                            Details : PTX-COVID19-B is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 04, 2022

                            Lead Product(s) : PTX-COVID19-B

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Providence Therapeutics

                            Canada arrow
                            Florida Innovation
                            Not Confirmed

                            Providence Therapeutics

                            Canada arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PTX-COVID-19-B

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : $2.1 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Providence Therapeutics Announces $2.118 Million USD in Funding to Support Process Development and Validation ...

                            Details : Providence is using the grant towards funding ongoing PTX-COVID19-B program process development and validation activities that will ultimately improve access of the vaccine in low- and middle-income countries (LMICs).

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            December 07, 2021

                            Lead Product(s) : PTX-COVID-19-B

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : $2.1 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Providence Therapeutics

                            Canada arrow
                            Florida Innovation
                            Not Confirmed

                            Providence Therapeutics

                            Canada arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PTX-COVID-19-B

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : Emergent BioSolutions

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics ...

                            Details : Under the terms of the five-year agreement, Emergent will provide current Good Manufacturing Practice (cGMP) manufacturing services for two presentations of the PTX-COVID19-B vaccine product, both the formulated bulk drug substance and finished drug prod...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            September 14, 2021

                            Lead Product(s) : PTX-COVID-19-B

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : Emergent BioSolutions

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Providence Therapeutics

                            Canada arrow
                            Florida Innovation
                            Not Confirmed

                            Providence Therapeutics

                            Canada arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PTX-COVID-19-B

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Everest Medicines

                            Deal Size : $600.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Everest Medicines Enters into Comprehensive Agreement with Providence Therapeutics to Advance mRNA Vaccines an...

                            Details : Everest and Providence have entered two separate definitive agreements (i) license rights to Providence’s mRNA COVID-19 vaccine candidate, PTX-COVID19-B in Asia emerging markets and (ii) establish a partnership to develop mRNA products globally.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : $100.0 million

                            September 13, 2021

                            Lead Product(s) : PTX-COVID-19-B

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Everest Medicines

                            Deal Size : $600.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Providence Therapeutics

                            Canada arrow
                            Florida Innovation
                            Not Confirmed

                            Providence Therapeutics

                            Canada arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PTX-COVID19-B

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This S...

                            Details : PTX-COVID19-B is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 21, 2021

                            Lead Product(s) : PTX-COVID19-B

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth